QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 x4-pharmaceuticals-announces-strategic-restructuring-with-50-workforce-reduction-expected-to-deliver-13m-annualized-cost-savings

Organizational restructuring including a 50% reduction in workforce that is anticipated to result in annualized cost savings of...

 stifel-maintains-buy-on-x4-pharmaceuticals-lowers-price-target-to-9

Stifel analyst Stephen Willey maintains X4 Pharmaceuticals (NASDAQ:XFOR) with a Buy and lowers the price target from $30 to $9.

 hc-wainwright--co-maintains-buy-on-x4-pharmaceuticals-lowers-price-target-to-35

HC Wainwright & Co. analyst Swayampakula Ramakanth maintains X4 Pharmaceuticals (NASDAQ:XFOR) with a Buy and lowers the ...

 x4-pharmaceuticals-announced-private-placement-in-public-equity-financing-of-approximately-60m

$60 million PIPE financing led by Coastlands Capital, Bain Capital Life Sciences and New Enterprise AssociatesNewly appointed b...

 x4-pharmaceuticals-enters-purchase-agreement-with-lincoln-park-can-sell-up-to-40m-in-stock

https://www.sec.gov/ix?doc=/Archives/edgar/data/1501697/000162828025032627/xfor-20250623.htm

 hc-wainwright--co-maintains-buy-on-x4-pharmaceuticals-raises-price-target-to-7

HC Wainwright & Co. analyst Swayampakula Ramakanth maintains X4 Pharmaceuticals (NASDAQ:XFOR) with a Buy and raises the ...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION